Clinical Trial Update: Switching From Consta® to Sustenna® in Patients With Schizophrenia

View source ↗

Summary

This clinical trial update reports the completion of a study evaluating switching from Risperdal Consta to Invega Sustenna in patients with schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• INVEGA SUSTENNA (PALIPERIDONE PALMITATE)
• Risperdal Consta (risperidone long-acting injectable)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Schizophrenia | Status: COMPLETED